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Abstract
Background: Death rattle (DR), caused by mucus in the respiratory tract, occurs in about half of patients who are in
the dying phase. Relatives often experience DR as distressing. Anticholinergics are recommended to treat DR,
although there is no evidence for the effect of these drugs. Anticholinergic drugs decrease the production of
mucus but do not affect existing mucus. We therefore hypothesize that these drugs are more effective when given
prophylactically.
Methods: We set up a randomized double-blind, placebo-controlled, multi-center study evaluating the efficacy of
prophylactically given subcutaneous scopolaminebutyl for the prevention of DR in the dying phase. The primary
outcome is the occurrence of DR defined as grade ≥ 2 according to the scale of Back measured by a nurse at 2
consecutive time points with an interval of 4 h. Secondary outcomes include adverse effects, quality of dying,
quality of life in the last three days and bereavement. A sub-study will explore the experience of participating in a
clinical trial in the dying phase from the perspective of relatives. Four hospices will include 200 patients.
Discussion: This is the first double-blind placebo-controlled study to prevent DR in patients in the hospice setting.
Research in dying patients is challenging. We will apply ethical and organizational strategies as suggested in the
literature.
Trial registration: The trial is retrospectively registered in the Dutch Trial register, identifier NTR 6438 June 2017.
EudractCT number 2016–002287-14.
Background
Death rattle is defined as ‘noisy breathing caused by the
presence of mucus in the upper respiratory tract’ [1, 2].
This phenomenon is a common symptom in the last days
of life, where 12–92% of patients in the dying phase have
been reported to develop death rattle [3]. In a recently
completed study in our own hospital, death rattle was re-
ported at least once in 40% (n = 149) of patients during
the dying phase, and in 35% (n = 130) of patients during the
last 24 h of life (Lokker ME, Heide Avd, Oldenmenger
WH, Rijt CCDvd, Zuylen Cv: Hydration and symptoms in
the last days of life, submitted). Nurses rated the symptom
as moderately severe in 23% and as severe or very severe in
39% of these patients, according to the scale of Back [4].
Professionals assume that patients do not experience
distress from death rattle because their consciousness is
reduced in the dying phase [5]. Reduced consciousness
is the main underlying cause of death rattle, as patients
are no longer able to cough up mucus [5]. For the rela-
tives, the rattling noise is unpleasant and disturbing, and
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they may fear that their loved one is suffering and might
be choking [3, 6]. Sixty-six percent of the relatives of pa-
tients who died in a palliative care unit indicated to ex-
perience death rattle as “very stressful” and 53% of them
said that there is a great need to improve the care for
and treatment of death rattle [7].
Anticholinergic medication is considered the stand-
ard treatment for death rattle. Treatment of death
rattle is regarded as an essential intervention in the
care of dying patients by specialists in palliative care
[8]. However, evidence for the efficacy of anticholin-
ergics is scarce. Until now, two randomized placebo
-controlled trials on anticholinergics for the treatment
of death rattle have been published, both with im-
portant limitations. One study was clearly underpow-
ered with the inclusion of seven patients [7], whereas
the other study only used a single dose of the
short-acting anticholinergic drug atropine [8]. Both
trials found no differences in the intensity of death
rattle and side effects between patients receiving anti-
cholinergics and placebo. Another study compared
the efficacy of three different anticholinergic drugs and
found no differences between the drugs on the presence
and intensity of death rattle [9]. The Dutch guideline on
care for dying patients is cautious in advising the use of
medication to treat death rattle [1]. Its recommended ap-
proach involves awareness, posture changes in bed and
extensive pro-active explanation to and communication
with relatives. Only if the rattle is still perceived as bur-
densome by relatives, anticholinergics may be considered.
Anticholinergics decrease the production of mucus
but do not affect existing mucus [10]. These drugs
may therefore be more effective if they are adminis-
tered prophylactically [9–11], before death rattle oc-
curs. [12] Scopolaminebutyl is the most frequently
prescribed anticholinergic drug for death rattle in the
Netherlands. We therefore designed a randomized
controlled trial (RCT) to answer our research ques-
tion: is scopolaminebutyl, when given prophylactically,
effective in preventing death rattle? In this paper, we
describe the protocol for this study and show how we
addressed the medical-ethical rules and Good Clinical
Practice guidelines [13] for this vulnerable patient
population.
To perform an RCT in patients in the dying phase
is a challenge. First, people in the last stage of their
lives can be considered vulnerable and the ethics of
asking vulnerable patients to participate in research is
still a topic of debate [14–16]. Secondly, including
sufficient numbers of patients has been demonstrated
to be a challenge in palliative and end-of-life care re-
search [17, 18]. And finally, a recent review showed
that gatekeeping is a serious threat to performing re-
search in palliative care [19]. We used several




The SILENCE study is a randomized double-blind,
placebo-controlled, multi-center study to measure the
efficacy of prophylactically administered scopolaminebu-
tyl in the prevention of death rattle in the dying phase.
This study will be conducted in four hospices. The trial
is designed in accordance with the Good Clinical Prac-
tice guidelines and according to the general ethical prin-
ciples outlined in the Declaration of Helsinki [13]. The
trial is retrospectively registered in the Dutch Trial regis-
ter, identifier NTR 6438; EudractCT number 2016–
002287-14. The study incorporates a sub-study: a ques-
tionnaire will be sent to relatives to gain insight in how
they experienced participation of their beloved one in
research.
Study population
Patients who are admitted to one of the participating
hospice facilities will be asked for participation. Inclu-
sion and exclusion criteria are described in Table 1.
When the multidisciplinary team agrees that the dying
phase has started, exclusion criteria will be checked




In the Netherlands, patients who are admitted to a hos-
pice facility in principle have a life expectancy of less
than three months and stay there until death. Standard
procedure at admission includes an interview about their
symptoms, care needs and expectations, by both a doc-
tor and a nurse.
Marking of the start of the dying phase, the last 2–
5 days of life, is based on recognition of a number of
signs by the nurses and doctors of the hospice: the pa-
tient is bedbound, only able to take sips of fluid, no
Table 1 Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Patient is admitted to one of
the participating hospices
Patient shows signs of active respiratory
infection
Patient is aware that the
admission will be up to death
Patient has a tracheostomy or tracheal
cannula
Patient’s life expectancy at
admission is at least 3 days
Patient uses systemic anticholinergic
drug(s) or octreotide (at admission or
when the dying phase starts)
Patient shows no signs of
disturbed consciousness
Patient has death rattle grade 1 or
higher on the scale of Back at the start
of the dying phase.
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longer able to swallow and take oral medication, and/or
subcomatose.
When this state is recognized, the patient and his fam-
ily are informed that death is imminent and they receive
explanation about the care given in these last days and
what symptoms might occur. They also receive a leaflet
with written information. The recognition of the dying
phase is a signal to start the Care Program for the Dying
(CPD). The CPD is a digital, structured template for care
in the last days and hours of life. This template defines
goals of care in all four domains of palliative care (e.g.
on pain, dyspnea, restlessness, nausea, death rattle, oral
hygiene, needs of family on psychological/spiritual do-
main, needs of the patients on psychological/spiritual
domain). The nursing staff evaluates these aspects of
care and symptoms every four hours. They report their
observations in the CPD. The observations are contin-
ued until the patient dies. The CPD is standard of care
in the hospice facilities that participate in this study.
Study
For this study, standard care procedures in the hospice
facilities are extended with some extra steps:
1. At admission: the doctor assesses if the patient
meets the inclusion criteria of the study. If so, the
patient is informed about the study and invited to
think about participation. Written information will
be given. After a period for reflection (maximum
48 h), the patient will get the opportunity for asking
additional questions and, if he/she is willing to
participate, to sign the informed consent form. The
patient and family are aware of the fact that the
study will not start immediately, but at the moment
the dying phase is recognized. The doctor also
informs the patient and relatives about the
questionnaire which will be sent to relatives three
months after the death of the patient.
2. Start of the dying phase: the actual study (the
intervention) starts with the recognition of the
dying phase. The exclusion criteria will be checked
again. In case of eligibility, the first dose of the
study medication scopolaminebutyl 20 mg (=1 ml)
or placebo (=1 ml NaCl 0.9%) will be administered
subcutaneously. The study medication will be
provided four times a day. The study medication is
packed in numbered boxes.
3. Care program: the CPD is extended with extra
observations related to the study. The extra
observations include restlessness, scored according
to the Vancouver Interaction and Calmness Scale
(VICS score) [20] and death rattle, scored according
to Back [4]. Nurses also report on the oral care
given.
4. Relatives: three months after a patient’s death,
relatives will be sent a questionnaire.
Integration of study procedures into regular care
The study procedures have been discussed with the
medical and nursing staff of the participating hospices to
assure integration of the study logistics in regular care
procedures. These procedures are largely similar for the
different hospices, but differ regarding the admission
process, contacts with pharmacists and procedures after
death. Standard care is given according to the guidelines
of the Netherlands Comprehensive Cancer Organization.
Only few adjustments were needed in the procedures
around the recognition of the dying phase and the care
given in the last days of life (e.g. oral care, posture
changes when (death) rattle starts, symptom manage-
ment). Staff of the hospices have much experience in
recognizing the dying phase and in working with the
CPD. All personnel has been involved in previous clin-
ical studies.
Training hospice staff
The multidisciplinary teams received a training about GCP.
Further, they were trained on site in implementing the
study protocol, procedures and data management. The
primary researcher (HvE) provided this training on site.
Substudy
Relatives will be sent a questionnaire three months after the
death of the patient. This questionnaire consists of several
general questions (demographic and non-demographic),
questions about the patient’s quality of life and quality of
death, the Dutch version of the inventory of traumatic grief
(ITG) [21] and questions about how participation of the pa-
tient in the study affected the quality of care according to
the relative. Relatives will also be invited to take part in
in-depth interviews about their experience of participating
in research in the dying phase.
Informed consent procedure
When a patient meets the inclusion criteria, he/she will
be informed about the study and asked to participate. A
patient information leaflet (PIL) is provided and time is
given to consider participation. After 48 h, the patient
can ask further questions and is asked for consent.
When the patient agrees, the PIL is signed twice, with
one copy for the patient and one for the researcher. Pa-
tients are free to withdraw from the study at any mo-
ment after signing informed consent.
Intervention
When the start of the dying phase is recognized, study
medication (scopolaminebutyl 20 mg (=1 ml) or placebo
(=1 ml NaCl 0.9%)) will be given four times a day
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subcutaneously. Treatment will be continued until death
or until the occurrence of death rattle with a severity of
grade ≥ 2 according to the scale of Back [4] at two con-
secutive measurements with an interval of 4 h. In the
latter case, medication will be regarded as “not effective”
and the study medication will be withdrawn. The patient
will then further receive care as usual.
Randomization
Block randomization with varying block sizes of 2–4 is
applied to create a randomization list for the study
medication (verum or placebo) within each center (i.e.
randomization is stratified by center).
As a result, verum and placebo are equally distributed
over both patients and sites.
Outcome measures
Primary outcome
The percentage of patients who develop death rattle, de-
fined as the occurrence of death rattle with a severity of
grade ≥ 2 according to the scale of Back at two consecu-
tive measurements with an interval of 4 h.
Secondary outcomes
– Time from the recognition of the dying phase until
the occurrence of death rattle (in hours)
– Occurrence of adverse events, i.e. urinary retention,
dry mouth and restlessness
– Quality of life during the last three days of life and
quality of dying, both according to the attending
nurse and relatives
– Bereavement of relatives
– Experience of relatives concerning the patient’s
participation in a (double-blind, placebo-controlled)
clinical trial
Measurement instruments
Table 2 provides an overview of measurement tools used
in the SILENCE study.
Data collection
Data collection starts when the dying phase starts and
the CPD is implemented. Collection of patient-related
information will be continued until death. All data will
be collected on electronic case report forms using
ALEA™, an online electronic database application as im-
plemented by the Clinical Trial Center of the Erasmus
MC Cancer institute (CTC).
Sample size calculation
For the power calculation we used data from a previous
study. In a sample of 400 deaths, 39% of the patients de-
veloped a death rattle with a severity of grade ≥ 2
according to the scale of Back (personal communica-
tion). We aim to reduce the occurrence of death rattle
from 39 to 19%. Given a two-sided significance level of
0.05 and 80% power, a total of 180 patients are required
based on a continuity-corrected Chi-square test. Taking
into account that 10% of the patients who have given in-
formed consent are expected to drop out before the ac-
tual start of the study because of sudden death or the
occurrence of exclusion criteria, 200 patients are needed
in total. Turnover in the four hospice settings is high: in
the first three months of 2015, 120 patients were admit-
ted, that is about 480 per year. Based on a 40% participa-
tion rate (= 192 out of 480), recognition of the dying
phase and application of the CPD in 80% of all consent-
ing patients(= 153 of 192) and a drop out of 10% it is
possible to include approximately 140 patients in a year.
This means that an inclusion period of approximately
18 months is needed.
Statistical analysis
All analyses will be performed in the most recent ver-
sion of IBM SSPS Statistics or Stata. Analyses will fol-
low the intention-to-treat principle. However, patients
initially randomized but considered ineligible after-
wards based on information that should have been
available before randomization, will be excluded from
all analyses. A p-value < 0.05 is considered to indicate
statistical significance.
Primary study parameter analysis
The occurrence of death rattle with a severity of
grade ≥ 2 according to the scale of Back in both
groups will be compared using the Chi squared test
or, if necessary (i.e., if an observed number ≤ 10 or an
expected number < 5 occurs in one of the cells of the
Table 2 Measurement tools
Measurement tool
Death rattle Scale of Back: 0 = no rattle, 1 = audible close
to the patient, 2 = audible standing at the
end of the bed, 3 = audible standing in the
door opening [4]
Restlessness Vancouver Interaction and Calmness Scale
(VICS score):
5 questions about restlessness scored on
a 6-point Likert scale [20]
Dry mouth/urinary
retention
Reported observations in CPD (agreed
standards, implemented for this study)
Grief Inventory of Traumatic Grief: 30 questions
about grief [21]
Quality of life Numeric rating scale (0 = worst quality
– 10 = best quality) [22]
Quality of dying Numeric rating scale: 0 = worst quality
– 10 = best quality); 15 qualitative descriptions
(peaceful, quiet, shocking, painful, etc.) [22]
to tick.
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2 × 2 table), the Fisher’s exact test, to test the statis-
tical significance of differences.
Secondary study parameters analysis
The time until the occurrence of death rattle will be
compared by means of the Kaplan-Meier method and
the log-rank test. The occurrence of adverse events, i.e.
urinary retention and dry mouth (yes/no) will be de-
scribed and compared using the Chi squared test or, if
necessary, Fisher’s exact test to assess statistical signifi-
cance. Restlessness will be compared using the t-test or,
if necessary, the Mann-Whitney U-test.
Quality of life during the last three days of life and
quality of dying will be described and compared by
means of a t-test (or Mann-Whitney U test if necessary).
The qualitative descriptions of the quality of dying will
be summarized. Bereavement of relatives according to
the ITG and experience of relatives on the patient’s par-
ticipating in a (double-blind, placebo-controlled) clinical
trial will be analyzed with descriptive statistics, and com-
pared using the Chi squared test for trends.
Ethical approval
This study is approved by the Medical Ethics committee
of the Erasmus MC Rotterdam, the Netherlands.
Discussion
The SILENCE study is a double-blind placebo-controlled
study on the effect of prophylactically administered scopo-
laminebutyl on the occurrence of death rattle. Performing
such a randomized clinical study in the dying phase is
challenging because of practical and ethical concerns. This
paper addresses how we designed the clinical trial and set
up the procedures to make the study feasible.
An RCT is the gold standard for demonstrating effi-
cacy of medication. There is a need for RCTs investigat-
ing symptom relief in the dying phase. The SILENCE
study will provide evidence on the treatment of death
rattle and its effect on quality of dying [3, 6, 7].
We are aware of the importance of a worthy dying
process. Dying is a unique and irreversible experience,
that cannot be redone and has to proceed as optimal as
possible, not only for the patient but also for their rela-
tives. The way a loved one dies can leave deep marks in
the memories of the relatives. In designing a prospective
study for a common symptom such as death rattle we
had to take into account several challenges.
The first issue concerns “gatekeeping”, related to the
vulnerability of the patients. “Gatekeeping” prevents eli-
gible patients to participate in research studies [18]. Kars
found five groups of “gate-keepers”: care professionals,
research ethics committees, health care facility man-
agers, relatives and researchers. To avoid gatekeeping in
our study, managers, care professionals and researchers
working in the four hospices have been involved in the
project, from formulating a research question which was
clinically and practically recognizable to the nursing
staff, in writing and commenting on the grant proposal,
to rewriting the protocol to standard operating proce-
dures. Above all efforts were made to arouse enthusiasm
for the research question in the multidisciplinary teams.
In line with this, we appointed a local researcher from
the local professional care teams. Although it is common
in clinical trials in hospitals that health care profes-
sionals (e.g. medical doctors and nurse practitioners) are
involved in research and act as principal investigators,
hospice staff is not accustomed to performing research,
which involves a risk of fall-out, disinterest, mistakes
in the study procedures and gate-keeping. In the lit-
erature on research in palliative care, several authors
recommend combining the task of investigator and
medical doctor; moreover, they plead for integration
of research with practical (end-of-life) care. Kaasa has
pleaded for “combined efforts between specialists in
palliative care and researchers in the basic science”,
[18] whereas Prince Paul and Casarett have advised to
integrate the tasks of research and medical care [16,
22]. This would lead to a better understanding of the
research process in professional care teams and make
performing research in the hospice setting more
standard. We followed their advice and trained a
medical doctor from each hospice as the local investi-
gator, as is also prescribed by GCP guidelines. Fur-
ther, the local medical doctors and nursing teams
were involved in setting up the study protocol. Be-
cause we also discussed and prepared the procedures
locally, the identity and working procedures of the
hospices could be preserved. In addition, all adminis-
trative activities for this study have been taken into
consideration. The workload does not significantly in-
crease because we will use standard data collection
instrument that is also used in regular care by the
participating teams: the Care Program for the dying
(CPD). Assessment of the occurrence of death rattle
is fully integrated in this program.
The second issue concerns the consent procedure. We
ask patients’ consent to participate in the study at their
admission in the hospice, when they are still capable of
understanding the information and able to decide
whether they want to participate. They may withdraw at
any moment after signing the informed consent form.
The actual study will start at the recognition of the dying
phase, at which moment most patients are not able of
giving consent due to their deteriorating condition. Rees
and colleagues stated that asking advanced consent
seems to be an acceptable alternative procedure, allow-
ing research in patients who are unable to give consent
at the time of randomization [23]. Patients who are
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admitted to a hospice facility in the Netherlands typically
stay there until death, which makes a strategy of ad-
vanced consent feasible.
Our third strategy involves evaluation of the views of
relatives about participation of their loved one in re-
search in the last days of life. We developed a question-
naire which will be sent to relatives three months after
the death of the patient. The challenge will be to sensi-
tively ask relatives for consent to send this questionnaire
at the moment the patient is admitted to the hospice.
This study has a few limitations. One limitation is the
recognition of the dying phase. Although the staff is very
experienced, inter-individual variability can occur. In the
training of the teams, there has been thorough attention
for signals that can indicate that the dying process has
started. Another limitation is that although all the strat-
egies presented aim to ensure adequate inclusion rates,
the turnover of patients in the hospices fluctuate over
time.
Conclusion
The SILENCE study will evaluate the efficacy of
prophylactically given scopolaminebutyl for the pre-
vention of death rattle in the dying phase. This may
improve treatment and care at the end of life. Legal
and medical-ethical requirements for clinical trials are
extensive and rigorous. We have implemented strat-
egies to comply with these requirements based on ad-
vice from the literature. The SILENCE study started
recruitment in April 2017 and is expected to be com-
pleted within 2 years.
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